Free press releases distribution network?

Agency / Source: Saladax Biomedical, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Saladax Biomedical Announces U.S Launch of MyImatinib™ Chemotherapy Exposure Optimization Test - Commercial Launch of MyImatinib™ Test Expands MyCare™ portfolio of Chemotherapy Exposure Optimization tests available from Saladax Biomedical Laboratories - Saladax.com
Saladax Biomedical Announces U.S Launch of MyImatinib™ Chemotherapy Exposure Optimization Test

 

PRZOOM - /newswire/ - Bethlehem, PA, United States, 2014/12/01 - Commercial Launch of MyImatinib™ Test Expands MyCare™ portfolio of Chemotherapy Exposure Optimization tests available from Saladax Biomedical Laboratories - Saladax.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic tests, today announced the commercial launch of the MyImatinib™ test. MyImatinib is part of the Saladax line of MyCare™ diagnostic tests that determine a patient’s exposure to chemotherapy in an effort to improve and personalize dosing.

The MyCare tests are simple blood tests that provide oncologists with specific information about each patient’s exposure to chemotherapy, helping the doctor to make informed decisions on drug dose adjustments, with the goals of maximizing the therapy’s effectiveness and limiting its potential side effects. The MyImatinib tests will be managed through the Saladax Biomedical Laboratories (SBL), the CLIA-certified division of Saladax Biomedical.

“We’re very excited to expand our portfolio of chemotherapy tests to include MyImatinib,” said Kevin Harter, Chairman, President and CEO of Saladax Biomedical. “Our own analysis shows that, in general, 50% of patients are not receiving an optimal chemotherapy dosage which reduces the effectiveness of the treatment or causes significant toxicity.”

Imatinib is used in the treatment of multiple cancers, and is marketed in the United States by Novartis as Gleevec®. MyImatinib joins the Saladax portfolio of tests that currently include My5-FU™, MyPaclitaxel™ and MyDocetaxel™. The MyCare tests are designed to provide oncologists with accurate, convenient and reliable information regarding Imatinib exposure levels.

“MyImatinib enables oncologists to administer tailored, personalized doses to chronic myeloid leukemia and gastrointestinal stromal tumor patients, allowing for optimal drug exposure and adherence over the course of their treatment,” added Harter. SBL anticipates expanding its menu of testing services to include more than a dozen new chemotherapy exposure optimization tests that Saladax Biomedical is currently developing.

About Saladax Biomedical, Inc.

Saladax Biomedical (saladax.com) is a leader in the development and deployment of high-quality diagnostic services and products, delivering actionable data to help physicians select and optimize the use of current and new pharmaceutical products, with the goals of improving health and positively impacting the economics of care… because no two patients are alike.

Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004 and is ISO 13485:2003 certified.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Saladax Biomedical, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Saladax Biomedical Announces U.S Launch of MyImatinib™ Chemotherapy Exposure Optimization Test

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Maura Donley - SO Tactics for Saladax 
717-574-5918 saladax[.]sotactics.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Saladax Biomedical, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Saladax Biomedical, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today